Drug Approval | February 24, 2024
Orchid Pharma's 'Exblifep' receives USFDA approval
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Sustainability is integral to Biocon's business purpose
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe
Launches collaborative centre for translational research in head and neck cancer
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Subscribe To Our Newsletter & Stay Updated
